Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1260019rdf:typepubmed:Citationlld:pubmed
pubmed-article:1260019lifeskim:mentionsumls-concept:C0035547lld:lifeskim
pubmed-article:1260019lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:1260019pubmed:issue1lld:pubmed
pubmed-article:1260019pubmed:dateCreated1976-7-6lld:pubmed
pubmed-article:1260019pubmed:abstractTextSeveral structural analogs of adenosylcobalamin, containing 2, 3, 4, 5 and 6 methylene carbons instead of the ribofuranose moiety, have been synthesized and their interaction with ribonucleotide reductase from Lactobacillus leichmannii has been investigated. Kinetic studies of the inhibition of the reductase by these analogs showed that the adeninylalkylcobalamins with 4, 5 and 6 carbons interposed between the adenine moiety and the cobalt atom are potent inhibitors of ribonucleotide reduction. The stronger interaction between adeninylpentylcobalamin and the enzyme than that between adenosylcobalamin and the enzyme suggests that the more flexible acyclic analog of adenosine requires fewer adjustments of the protein upon binding.lld:pubmed
pubmed-article:1260019pubmed:languageenglld:pubmed
pubmed-article:1260019pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1260019pubmed:citationSubsetIMlld:pubmed
pubmed-article:1260019pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1260019pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1260019pubmed:statusMEDLINElld:pubmed
pubmed-article:1260019pubmed:monthMarlld:pubmed
pubmed-article:1260019pubmed:issn0006-3002lld:pubmed
pubmed-article:1260019pubmed:authorpubmed-author:GrantM EMElld:pubmed
pubmed-article:1260019pubmed:authorpubmed-author:HogenkampH...lld:pubmed
pubmed-article:1260019pubmed:authorpubmed-author:SandoG NGNlld:pubmed
pubmed-article:1260019pubmed:issnTypePrintlld:pubmed
pubmed-article:1260019pubmed:day25lld:pubmed
pubmed-article:1260019pubmed:volume428lld:pubmed
pubmed-article:1260019pubmed:ownerNLMlld:pubmed
pubmed-article:1260019pubmed:authorsCompleteYlld:pubmed
pubmed-article:1260019pubmed:pagination228-32lld:pubmed
pubmed-article:1260019pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1260019pubmed:meshHeadingpubmed-meshheading:1260019-...lld:pubmed
pubmed-article:1260019pubmed:meshHeadingpubmed-meshheading:1260019-...lld:pubmed
pubmed-article:1260019pubmed:meshHeadingpubmed-meshheading:1260019-...lld:pubmed
pubmed-article:1260019pubmed:meshHeadingpubmed-meshheading:1260019-...lld:pubmed
pubmed-article:1260019pubmed:meshHeadingpubmed-meshheading:1260019-...lld:pubmed
pubmed-article:1260019pubmed:meshHeadingpubmed-meshheading:1260019-...lld:pubmed
pubmed-article:1260019pubmed:meshHeadingpubmed-meshheading:1260019-...lld:pubmed
pubmed-article:1260019pubmed:year1976lld:pubmed
pubmed-article:1260019pubmed:articleTitleThe interaction of adeninylalkylcobalamins with ribonucleotide reductase.lld:pubmed
pubmed-article:1260019pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1260019pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1260019lld:pubmed